Prednisone
Indications
Prednisone has one of the broadest FDA-approved indication lists of any drug — the labelling spans 13 categories of conditions where corticosteroid anti-inflammatory or immunosuppressive activity is desired, plus replacement therapy for adrenocortical insufficiency. Because the indications cover dozens of distinct diseases, the table below groups them by category. In nearly every indication, prednisone is used as adjunctive therapy or for short-term flare control rather than as monotherapy or definitive treatment.
| Category | FDA-Approved Indications | Status |
|---|---|---|
| Endocrine | Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone preferred); congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia of malignancy | FDA Approved |
| Rheumatologic | Acute gouty arthritis (short-term); rheumatoid arthritis (including JRA); psoriatic arthritis; ankylosing spondylitis; SLE; vasculitis; polymyositis/dermatomyositis; polymyalgia rheumatica; Sjögren’s syndrome; relapsing polychondritis | FDA Approved |
| Allergic | Severe allergic conditions intractable to conventional therapy: atopic dermatitis, drug hypersensitivity, allergic rhinitis (seasonal/perennial), serum sickness | FDA Approved |
| Dermatologic | Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis; contact dermatitis | FDA Approved |
| Pulmonary | Asthma; acute COPD exacerbations; allergic bronchopulmonary aspergillosis; idiopathic eosinophilic pneumonias; idiopathic pulmonary fibrosis; symptomatic sarcoidosis; cryptogenic organizing pneumonia; aspiration pneumonitis; PCP with hypoxemia (HIV+); fulminating/disseminated pulmonary TB (with anti-TB therapy); hypersensitivity pneumonitis | FDA Approved |
| Hematologic | Idiopathic thrombocytopenic purpura (adults); secondary thrombocytopenia (adults); acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia | FDA Approved |
| Gastrointestinal | Crohn’s disease and ulcerative colitis (acute episodes) | FDA Approved |
| Neurologic | Acute exacerbations of multiple sclerosis; cerebral edema with primary or metastatic brain tumor, craniotomy, or head injury | FDA Approved |
| Renal | Nephrotic syndrome (idiopathic or due to lupus erythematosus, without uremia) | FDA Approved |
| Ophthalmic | Sympathetic ophthalmia; uveitis and ocular inflammation unresponsive to topical steroids | FDA Approved |
| Neoplastic | Acute leukemia; aggressive lymphomas (component of CHOP, R-CHOP, and similar regimens) | FDA Approved |
| Transplantation | Acute or chronic solid organ rejection | FDA Approved |
| Specific Infectious Diseases | Trichinosis with neurologic or myocardial involvement; tuberculous meningitis with subarachnoid block (with anti-TB chemotherapy) | FDA Approved |
Giant cell arteritis (high evidence): 40–60 mg/day initial, taper over 12–24 months — guideline-recommended (ACR/VF 2021), although prednisone itself is not specifically labelled for GCA.
Bell’s palsy within 72 h (high evidence): 50–60 mg/day for 5–10 days — improves recovery rates per multiple RCTs.
Severe COVID-19 with oxygen requirement (high evidence): Dexamethasone 6 mg/day is the standard per RECOVERY trial; prednisone 40 mg/day is an accepted equivalent when dexamethasone is unavailable.
Recurrent pregnancy loss, IVF support, and other reproductive indications (low to moderate evidence): Practice varies; not generally recommended outside specific protocols.
Acute spinal cord injury (very low evidence): High-dose methylprednisolone protocols are no longer routinely recommended; oral prednisone has no role in this setting.
Dosing
Prednisone dose is individualized to disease activity, response, and risk of toxicity rather than to body weight or tablet strength. The FDA labelling describes the typical initial range as 5 to 60 mg per day, with the actual starting dose chosen by the clinical scenario. After clinical response, doses are tapered to the lowest amount that maintains disease control. Below are common scenario-based regimens drawn from the FDA labelling and major guidelines; doses for chemotherapy and transplantation regimens follow protocol-specific schedules and are not summarized here.
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance / Taper | Typical Maximum | Notes |
|---|---|---|---|---|
| Rheumatoid arthritis flare (adjunct to DMARD) | 5–10 mg PO daily | Taper to lowest effective dose | 10 mg/day for routine flare use | Higher doses (e.g., 20–60 mg) reserved for severe flare; consider osteoporosis prophylaxis if ≥7.5 mg/day for ≥3 months RAYOS Phase 3: 5 mg at bedtime improved morning stiffness vs placebo |
| Polymyalgia rheumatica | 12.5–25 mg PO daily | Taper by 2.5 mg every 2–4 wk to 10 mg/day, then 1 mg/month | 25 mg/day initial | Per ACR/EULAR 2015. Most patients require 1–2 years of therapy; ~40% relapse during taper |
| Giant cell arteritis (off-label) | 40–60 mg PO daily | Taper over 12–24 months | 60 mg/day (or 1 mg/kg) | Higher initial doses (or IV pulse methylprednisolone) for visual involvement. Tocilizumab as steroid-sparing add-on per ACR/VF 2021 |
| Acute asthma exacerbation (adult, outpatient or inpatient) | 40–60 mg PO daily | Continue × 5–7 days; no taper needed if course ≤7 days | 60 mg/day | Per GINA 2024. Single morning dose; no tapering required for short courses ≤2–3 weeks |
| Acute COPD exacerbation | 40 mg PO daily × 5 days | Stop after 5 days (no taper) | 40 mg/day × 5 days (REDUCE) | 5-day course non-inferior to 14-day course (Leuppi 2013; GOLD 2024) |
| IBD flare (Crohn’s, UC) | 40–60 mg PO daily | Taper by 5–10 mg/wk to 20 mg, then 5 mg/wk to off | 60 mg/day or 1 mg/kg | Use as bridge to a steroid-sparing agent (immunomodulator, biologic). Avoid prolonged use as maintenance |
| Acute multiple sclerosis exacerbation | 200 mg PO daily × 1 wk → 80 mg every other day × 1 mo | Stop after the listed regimen | 200 mg/day × 7 days | Per FDA prednisone labelling. In current practice, IV methylprednisolone 1 g/day × 3–5 days (with or without oral taper) is more commonly used |
| Idiopathic thrombocytopenic purpura (adults) | 1 mg/kg/day | Taper based on platelet response over 4–6 weeks | 80 mg/day | Per ASH 2019. High-dose pulse dexamethasone (40 mg × 4 days) is an alternative |
| Acute gouty arthritis (when NSAIDs/colchicine contraindicated) | 30–40 mg PO daily | Continue × 5 days, then taper over 7–10 days | 40 mg/day | Per ACR 2020. Useful in patients with renal impairment or anticoagulation |
| Bell’s palsy (off-label, <72 h onset) | 60 mg PO daily × 5 days, then taper | 10-day total course | 60 mg/day | Per AAN 2012; addition of valacyclovir does not improve outcome over steroid alone |
| Severe COVID-19 (oxygen-dependent, off-label equivalent) | 40 mg PO daily × up to 10 days | Stop at hospital discharge or 10 days | 40 mg/day | Equivalent to dexamethasone 6 mg (RECOVERY trial). Use dexamethasone first-line where available |
| Adrenal insufficiency (replacement, when prednisone is selected) | 3–5 mg PO every morning | Long-term physiologic replacement | 7.5 mg/day | Hydrocortisone (15–25 mg/day in 2–3 divided doses) is preferred per Endocrine Society 2016 because of more physiologic profile. Stress-dose coverage required for illness, surgery, trauma |
Pediatric Dosing (Selected Indications)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Acute asthma exacerbation | 1–2 mg/kg/day PO (max 60 mg/day) | 3–10 days | Per NHLBI / NAEPP. No taper needed if ≤7 days |
| Idiopathic nephrotic syndrome (initial) | 60 mg/m²/day PO (max 60 mg) in 1–3 divided doses | 4–6 weeks, then 40 mg/m² every other day × 2–5 months | Per KDIGO 2021. Follow growth velocity carefully |
| Aggressive lymphomas / acute lymphoblastic leukemia (induction) | Protocol-specific (commonly 40 mg/m²/day or 60 mg/m²/day) | Per chemotherapy protocol | Doses follow individual induction regimens (e.g., COG ALL protocols). FDA labelling supports use ≥1 month of age |
| Other pediatric indications | 0.05–2 mg/kg/day in 1–4 divided doses | Disease- and response-dependent | Always titrate to lowest effective dose; monitor growth velocity |
Tapering Principles
Patients on prednisone for >2–3 weeks at supraphysiologic doses (typically >5 mg/day) may have HPA-axis suppression and require tapering before discontinuation. There is no single validated taper schedule; the principles below align with the FDA labelling and clinical consensus:
- Courses ≤7 days at any dose: No taper required (HPA-axis recovery within days).
- Courses 1–3 weeks at >20 mg/day: Optional brief taper over 5–7 days.
- Courses 3 weeks to 3 months: Taper by 5–10 mg every 1–2 weeks above 20 mg/day, then 2.5–5 mg every 1–2 weeks below 20 mg/day, then 1 mg every 1–2 weeks below 10 mg/day.
- Courses >3 months: Slower tapers (1 mg every 2–4 weeks below 10 mg/day) and consider morning cortisol or ACTH stimulation testing once at physiologic-equivalent dose (≤5 mg/day) before complete withdrawal.
- Stress-dose coverage may be required for major illness, surgery, or trauma during the taper and for up to 12 months after discontinuation.
Special Populations
- Hepatic impairment: Severe liver disease (cirrhosis, fulminant hepatitis) may impair conversion of prednisone to active prednisolone; prednisolone is preferred in this setting. No formal dose adjustment for mild–moderate impairment.
- Renal impairment: No specific dose adjustment, but elderly patients with reduced renal function may have higher exposures; start at the lower end of the dosing range.
- Older adults (≥65 years): Higher unbound prednisolone exposures and reduced clearance per the FDA labelling. Osteoporosis risk is the dominant concern; doses ≥7.5 mg/day for ≥3 months warrant bone-protection strategies and DEXA monitoring.
- Pediatrics: Use lowest effective dose; growth velocity is a sensitive marker of systemic exposure and may decline at low doses without HPA-axis suppression on biochemical testing.
- Pregnancy: Maternal first-trimester corticosteroid use has been associated with a small increase in orofacial clefts (from ~1/1,000 to 3–5/1,000 infants in observational studies). Intrauterine growth restriction and reduced birth weight have been reported with prolonged use. When prednisone is required during pregnancy, use the lowest effective dose.
- Lactation: Prednisolone concentrations in human milk are 5–25% of maternal serum levels; total infant daily dose is approximately 0.14% of the maternal daily dose. Generally compatible with breastfeeding; for doses >20 mg/day, some authorities recommend waiting 4 hours after a dose before breastfeeding.
Endogenous cortisol secretion peaks between 2 a.m. and 8 a.m. and is lowest between 4 p.m. and midnight. A single morning dose of prednisone produces the least HPA-axis suppression because it mimics the natural circadian peak; divided dosing or evening dosing produces more suppression for the same total daily dose. The exception is delayed-release prednisone (Rayos), which is taken at bedtime so that drug release coincides with the early-morning rise in disease activity — particularly the morning stiffness of rheumatoid arthritis. For all other regimens, default to a single morning dose unless there is a compelling clinical reason to divide.
Pharmacology
Mechanism of Action
Prednisone is a synthetic glucocorticoid prodrug that is rapidly and almost completely converted by hepatic 11β-hydroxysteroid dehydrogenase to its active metabolite prednisolone. Prednisolone diffuses across the cell membrane and binds the cytosolic glucocorticoid receptor; the activated complex translocates to the nucleus, where it modulates transcription of inflammatory and immune-response genes through two principal mechanisms.
Transactivation upregulates anti-inflammatory genes including lipocortin-1 (annexin A1), which inhibits phospholipase A2 and thereby reduces release of arachidonic acid and downstream prostaglandins and leukotrienes. Transrepression inhibits the activity of pro-inflammatory transcription factors NF-κB and AP-1, producing broad suppression of cytokine synthesis (IL-1, IL-2, IL-6, TNF-α, IFN-γ), adhesion molecule expression, and the recruitment and function of neutrophils, eosinophils, lymphocytes, and macrophages. The clinical anti-inflammatory effect is evident within hours; the immunosuppressive effect — including reduction of circulating lymphocytes through redistribution to lymphoid tissue — develops over days. At higher doses, prednisolone also produces measurable mineralocorticoid activity (sodium retention, potassium loss, increased blood pressure) although less prominently than the parent endogenous hormone hydrocortisone.
The pharmacological effects of prednisone described in the FDA labelling include promotion of gluconeogenesis, increased hepatic glycogen deposition, anti-insulin activity, increased protein catabolism, increased lipolysis and fat redistribution, increased glomerular filtration with elevated urinary urate excretion, and increased calcium excretion. Eosinophil and lymphocyte production is suppressed while erythropoiesis and neutrophil production are stimulated. These metabolic effects underlie much of the toxicity profile (hyperglycemia, muscle wasting, fat redistribution, osteoporosis) observed with prolonged use.
Glucocorticoid Potency Comparison
Prednisone is classed as an intermediate-acting glucocorticoid based on its biological half-life of approximately 12–36 hours. The FDA labelling specifies the following equipotent oral and intravenous doses:
| Glucocorticoid | Equipotent Dose | Relative Anti-inflammatory Potency | Relative Mineralocorticoid Potency | Biological Half-life Class |
|---|---|---|---|---|
| Hydrocortisone | 20 mg | 1 | 1 | Short-acting (8–12 h) |
| Cortisone | 25 mg | 0.8 | 0.8 | Short-acting |
| Prednisone | 5 mg | 4 | 0.8 | Intermediate (12–36 h) |
| Prednisolone | 5 mg | 4 | 0.8 | Intermediate |
| Methylprednisolone | 4 mg | 5 | 0.5 | Intermediate |
| Triamcinolone | 4 mg | 5 | 0 | Intermediate |
| Dexamethasone | 0.75 mg | 25–30 | ~0 | Long-acting (36–72 h) |
| Betamethasone | 0.75 mg | 25–30 | ~0 | Long-acting |
Pharmacokinetics
| Parameter | Value | Comment |
|---|---|---|
| Bioavailability | ~80% (oral) | Immediate-release formulation; food does not meaningfully impair absorption of IR tablets |
| Tmax | ~2 h (IR); ~6.5 h (DR Rayos) | Delayed-release coating delays drug release by approximately 4 hours; must be taken with food |
| Volume of distribution | ~0.4–1 L/kg (prednisolone) | Distributes into most tissues; crosses placenta and into breast milk |
| Protein binding | ~70–95% (concentration-dependent) | Primarily transcortin (cortisol-binding globulin) at low concentrations; albumin at higher concentrations. Free fraction increases as transcortin saturates |
| Metabolism | Hepatic; CYP3A4 substrate | Prednisone is rapidly and completely converted to active prednisolone by hepatic 11β-HSD; prednisolone is further metabolized in the liver and excreted as sulfate and glucuronide conjugates. Prednisolone exposure is 4–6× higher than prednisone |
| Terminal half-life | ~2–3 h | Pharmacological/biological half-life is much longer (12–36 h) due to receptor-binding and downstream genomic effects |
| Excretion | Urine (predominantly as conjugates) | Negligible biliary excretion |
Prednisone exhibits dose-proportional pharmacokinetics across the 1–5 mg dose range studied for the delayed-release formulation. The pharmacokinetics are not meaningfully altered by mild-to-moderate renal impairment, but elderly patients have higher unbound prednisolone exposures and reduced clearance; the FDA labelling recommends starting at the lower end of the dosing range in older adults. In severe hepatic impairment, conversion of prednisone to prednisolone may be impaired and direct administration of prednisolone is preferred.
Side Effects
Prednisone has been in clinical use since 1955 and its adverse-effect profile is among the most thoroughly characterized of any drug. Because the FDA labelling lists adverse reactions by organ system without modern RCT-derived incidence rates, the frequencies below are drawn from the FDA labelling combined with systematic reviews of low-to-medium dose chronic glucocorticoid therapy in inflammatory diseases (Da Silva 2006; Hoes 2009) and the ACR 2017 guideline on glucocorticoid-induced osteoporosis. The single most important factor governing toxicity is cumulative dose × duration: most adverse effects are minimal with short courses (≤3 weeks) at any reasonable dose, increase substantially with chronic use, and become near-universal with long-term doses ≥10 mg/day. The RAYOS Phase 3 RA trial (350 patients, 12 weeks, doses 3–10 mg/day) did not raise new safety concerns beyond the well-established profile of immediate-release prednisone.
| Effect | Frequency / Onset | Clinical Action |
|---|---|---|
| Increased appetite & weight gain | Very common Within weeks; cumulative | Counsel on portion control, regular weighing; weight gain >5% body weight should prompt dose review |
| Cushingoid features (moon face, central obesity, dorsocervical fat pad, striae) | Very common with ≥10 mg/day chronic use Weeks to months | Largely cosmetic; reverses with dose reduction. Counsel patients in advance to set expectations |
| HPA-axis suppression | Common after >3 weeks at >5 mg/day Days to weeks | Taper after prolonged use; consider stress-dose coverage for surgery/illness; recovery may take months |
| Fluid retention and mild lower-extremity edema | Common Days to weeks | Reduce dietary sodium; usually resolves on dose reduction. More prominent with hydrocortisone than with prednisone |
| Hyperglycemia / impaired glucose tolerance | Common; near-universal in pre-diabetes Days to weeks | Check fasting and 2-hour postprandial glucose at baseline and during chronic therapy. May unmask latent diabetes; insulin requirements rise in known diabetics |
| Mood changes (euphoria, irritability, mood swings, insomnia) | Common, especially at higher doses Days; may begin with the first dose | Warn all patients prospectively. Take dose in the morning to reduce insomnia. Severe mood disturbance warrants dose reduction or discontinuation |
| Hypertension / blood pressure elevation | Common Weeks | Monitor BP at each visit during chronic therapy; may require initiation or intensification of antihypertensives |
| Skin changes (thinning, easy bruising, acne, striae, impaired wound healing) | Common with chronic use Months | Counsel; partially reversible with dose reduction. Striae may be permanent |
| Effect | Frequency / Onset | Clinical Action |
|---|---|---|
| Decreased bone density / osteoporotic fracture | Significant fracture risk at ≥7.5 mg/day for ≥3 months Greatest bone loss in first 3–6 months | Per ACR 2017 GIO guideline: assess fracture risk and initiate bone-protective therapy (calcium 1,000–1,200 mg/day, vitamin D 600–800 IU/day, plus bisphosphonate if at moderate-to-high risk). DEXA at baseline and every 1–3 years |
| Cataracts (posterior subcapsular) | Common with prolonged use; dose- and duration-dependent Months to years | Annual ophthalmologic exam during chronic therapy; cataracts are largely irreversible but surgically treatable |
| Glaucoma / increased intraocular pressure | ~5% of chronic users; higher in steroid-responders Weeks to months | Monitor IOP if therapy continues >6 weeks (FDA recommendation). Higher risk with personal or family history of open-angle glaucoma |
| Increased infection risk (bacterial, viral, fungal, opportunistic) | Risk increases with dose and duration Throughout therapy | Screen for latent TB and hepatitis B before chronic therapy. Consider PCP prophylaxis at sustained doses ≥20 mg/day for ≥4 weeks. Avoid live vaccines at immunosuppressive doses |
| Hypokalemia and metabolic alkalosis | Common with high doses or concomitant diuretics/amphotericin Days to weeks | Monitor potassium during chronic therapy; supplement as needed. Particularly important in patients on digoxin or with cardiac arrhythmias |
| Myopathy (proximal muscle weakness) | Common with chronic high doses Weeks to months | Counsel on resistance exercise; CK is typically normal in steroid myopathy. Reverses slowly with dose reduction |
| Menstrual irregularities | Common Variable | Reassure; resolves with discontinuation |
| Growth suppression (pediatric) | Common with chronic use Detectable within months | Monitor growth velocity (more sensitive than HPA testing). Use lowest effective dose; alternate-day dosing when feasible |
| Effect | Frequency / Onset | Clinical Action |
|---|---|---|
| Adrenal crisis (during withdrawal or stress) | Uncommon but life-threatening Onset within hours of stress in suppressed patient | Provide MedicAlert identification, written stress-dose plan, and emergency hydrocortisone for any patient on chronic supraphysiologic doses or prolonged taper. Treat with IV hydrocortisone 100 mg + saline for hypotension/shock during stress |
| Steroid-induced psychosis or severe depression | ~3–6% with high-dose use Days to weeks; higher risk at >40 mg/day prednisone-equivalent | Discontinue or rapidly reduce dose under cover of antipsychotic if needed. Symptoms typically resolve within 6 weeks of discontinuation |
| Gastrointestinal perforation | Uncommon overall; higher in IBD, diverticulitis, recent intestinal anastomosis, active peptic ulcer During therapy; signs may be masked | Maintain low threshold for imaging in chronically treated patients with new abdominal pain. Coadministration with NSAIDs further increases risk |
| Reactivation of latent infection (TB, hepatitis B, Strongyloides, herpes zoster) | Uncommon but potentially fatal Weeks to months into therapy | Screen for latent TB (IGRA or TST) and hepatitis B before chronic immunosuppressive therapy. Consider Strongyloides screening in patients from endemic areas. Treat reactivations promptly |
| Cardiovascular events (MI, heart failure exacerbation) | Increased risk at higher doses; LV free wall rupture has been reported after recent MI During therapy | Use with great caution within 30 days of MI per the FDA labelling. Address cardiovascular risk factors aggressively in chronic users |
| Osteonecrosis (avascular necrosis) of the femoral or humeral head | Uncommon but well-described; risk increases with cumulative dose and pulse therapy Months to years | MRI for new persistent hip or shoulder pain in chronic users. Discontinuation does not reverse established osteonecrosis |
| Acute myopathy (high-dose, neuromuscular disease) | Rare Days to weeks at very high doses, especially with concomitant neuromuscular blockers | Generalized weakness involving ocular and respiratory muscles; CK may be elevated. Discontinue corticosteroid; recovery takes weeks to years |
| Anaphylaxis / angioedema | Rare Minutes to hours of exposure | Discontinue immediately; treat with epinephrine and supportive care. True hypersensitivity is rare but documented |
Patients who have received supraphysiologic doses (typically >5 mg/day) for more than 2–3 weeks are at risk for HPA-axis suppression. Abrupt discontinuation in a suppressed patient can produce a withdrawal syndrome that overlaps with — but is not identical to — adrenal insufficiency, characterized by fatigue, anorexia, nausea, weight loss, arthralgia, myalgia, headache, and orthostatic hypotension. The syndrome is typically self-limited but may unmask frank adrenal crisis under physiologic stress. There is no validated biochemical test that perfectly predicts who will become symptomatic on withdrawal; clinical judgement and gradual tapering (see Dosing) remain the cornerstones of safe discontinuation.
Drug Interactions
Prednisone has a large number of clinically relevant interactions, mediated primarily through (1) CYP3A4 metabolism of the active metabolite prednisolone, (2) glucocorticoid effects on glucose, potassium, and the GI tract, and (3) immunosuppressive effects altering vaccine response. The cards below summarize the most important interactions from the FDA labelling, organized by clinical management priority.
Monitoring
The intensity of monitoring scales with dose and intended duration of therapy. Short courses (≤7 days) at any reasonable dose require essentially no laboratory monitoring beyond routine clinical assessment. Chronic therapy at supraphysiologic doses requires structured surveillance for the well-described metabolic, cardiovascular, ophthalmologic, infectious, and skeletal complications.
- Blood PressureBaseline, every visit during chronic useRoutineFDA labelling specifies regular BP monitoring during prolonged therapy. Initiate or adjust antihypertensive therapy as needed. Sodium restriction may help in marginal cases
- Body WeightBaseline, every visitRoutineTrack to detect rapid fluid retention and Cushingoid weight gain. Counsel proactively on diet
- Glucose (Fasting + 2-hour Postprandial)Baseline; routinely during chronic useRoutineFDA labelling specifies 2-hour postprandial glucose during prolonged therapy. HbA1c is less sensitive to steroid-induced hyperglycemia. In known diabetics, intensify home glucose monitoring
- Serum PotassiumBaseline; periodically during chronic useRoutineFDA labelling specifies regular potassium monitoring during prolonged therapy. More frequent monitoring on diuretics, amphotericin B, or digoxin
- Bone Mineral Density (DEXA)Baseline if ≥7.5 mg/day expected for ≥3 months; every 1–3 yearsRoutinePer ACR 2017 GIO guideline. Pair with calcium 1,000–1,200 mg/day, vitamin D 600–800 IU/day, and consider bisphosphonate therapy for moderate-to-high fracture risk patients on chronic glucocorticoids
- Intraocular PressureIf therapy ≥6 weeksRoutinePer FDA labelling. Annual ophthalmologic exam during chronic therapy includes IOP measurement and slit-lamp evaluation for posterior subcapsular cataracts
- Latent TB Screening (IGRA or TST)Before chronic immunosuppressive therapyTriggeredPer FDA labelling. Treat latent TB before or concurrent with prolonged corticosteroid therapy in any patient with a positive screen
- Hepatitis B Serology (HBsAg, anti-HBc)Before chronic immunosuppressive therapyTriggeredPer FDA labelling. HBV reactivation can occur in carriers and even in patients with apparently resolved infection; consult hepatology for prophylactic antiviral consideration
- Growth Velocity (Pediatric)Every visit during chronic therapyRoutineMore sensitive than HPA-axis testing per FDA labelling. Plot height velocity on growth curve; titrate to lowest effective dose
- Morning Cortisol or ACTH (Cosyntropin) Stimulation TestBefore stopping after long-term high-dose useTriggeredPer Endocrine Society 2016. Consider once tapered to physiologic-equivalent dose (≤5 mg/day) and held for 24 h. Morning cortisol >10 µg/dL or normal ACTH-stim response generally indicates HPA recovery; intermediate values warrant continued precaution
- Mood / Mental HealthEvery visit; especially first monthRoutineInquire about insomnia, mood elevation, depression, suicidal ideation. Higher risk at doses ≥40 mg/day prednisone-equivalent or in patients with prior psychiatric history
- Signs of InfectionEvery visitRoutineCounsel patient to report fever, productive cough, dysuria, or new abdominal pain promptly. Corticosteroids may mask classic infection signs (fever, leukocytosis pattern)
Contraindications
The FDA labelling for prednisone lists only one absolute contraindication. The labelling otherwise describes a long list of conditions in which corticosteroid therapy carries elevated risk and warrants either avoidance or careful clinical judgement; these are framed as cautions rather than contraindications because the benefit may outweigh the risk in selected scenarios. The lists below organize this distinction.
Absolute Contraindications
Known hypersensitivity to prednisone or to any component of the formulation. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy.
Relative Contraindications and Significant Cautions
Systemic fungal infections — corticosteroids may exacerbate. Use only if needed to control drug reactions and consider antifungal coverage.
Live or live-attenuated vaccines at immunosuppressive doses — risk of disseminated vaccine-strain disease (FDA §5.8).
Cerebral malaria — corticosteroid use is associated with worse outcomes and should be avoided (FDA §5.2).
Active untreated tuberculosis — corticosteroids may permit dissemination. Use only with concurrent appropriate anti-TB chemotherapy as in tuberculous meningitis.
Recent myocardial infarction — literature reports of left-ventricular free-wall rupture with corticosteroid use after recent MI; use with great caution within 30 days (FDA §5.3).
Untreated active ocular herpes simplex — risk of corneal perforation (FDA §5.7).
Existing peptic ulcer disease, diverticulitis, recent intestinal anastomosis — increased GI perforation risk (FDA §5.4).
Latent tuberculosis or tuberculin reactivity — provide chemoprophylaxis during prolonged therapy.
Hepatitis B carriers or resolved hepatitis B — risk of viral reactivation; co-management with hepatology.
Patients from tropical regions, unexplained eosinophilia, or unexplained diarrhea — rule out latent Strongyloides infestation; risk of fatal hyperinfection.
Myasthenia gravis — risk of severe weakness during initiation; introduce in monitored setting (FDA §7.3).
Uncontrolled hypertension, congestive heart failure, or significant renal impairment — sodium retention and BP elevation may worsen disease (FDA §5.3).
Pregnancy — small increased risk of orofacial clefts with first-trimester use; intrauterine growth restriction with prolonged use (FDA §5.10).
Diabetes mellitus — anticipate worsening glycemic control; intensify monitoring and therapy.
Psychiatric history — particularly bipolar disorder, prior steroid-induced psychosis; involve mental-health expertise for prolonged or high-dose therapy.
Patient Counselling
Patient understanding is central to safe use of prednisone. The FDA-required counselling points below should be reinforced at initiation and at each follow-up visit, particularly for patients on chronic therapy. A written patient information sheet and MedicAlert identification (for chronic users) substantially reduce the risk of catastrophic events such as adrenal crisis under stress.
Sources
- RAYOS (prednisone) delayed-release tablets — US prescribing information. Horizon Therapeutics USA, Inc. NDA 202020. Revised March 2024. accessdata.fda.gov/drugsatfda_docs/label/2024/202020s013lbl.pdf Most recent FDA-approved labelling for prednisone (delayed-release formulation). The IR-tablet labelling (e.g., DailyMed setid 10fe5a3b-84dc-4600-87c2-b80c97ce18cf for generic prednisone) reflects the same indications and warnings.
- Prednisone tablets, USP — generic prescribing information. DailyMed (US National Library of Medicine). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10fe5a3b-84dc-4600-87c2-b80c97ce18cf FDA-approved labelling for generic immediate-release prednisone tablets, covering the full historical indication list that long predates the modern Highlights format.
- Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205–214. doi.org/10.1016/S0140-6736(08)60132-4 Pivotal CAPRA-1 trial supporting the bedtime delayed-release Rayos formulation; demonstrated reduction in morning stiffness duration vs immediate-release prednisone at the same total daily dose.
- Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi.org/10.1002/art.40137 ACR guideline establishing the ≥7.5 mg/day for ≥3 months threshold for fracture-risk assessment and the bone-protection treatment algorithm for chronic glucocorticoid users.
- Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389. doi.org/10.1210/jc.2015-1710 Endocrine Society reference for replacement-dose corticosteroid regimens and stress-dose coverage; widely applied to glucocorticoid-induced secondary adrenal insufficiency.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–760. doi.org/10.1002/acr.24180 ACR gout guideline supporting oral glucocorticoids (e.g., prednisone 30–40 mg/day for 5 days) as first-line therapy for acute flares when NSAIDs and colchicine are contraindicated.
- Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology / Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349–1365. doi.org/10.1002/art.41774 ACR/VF guideline endorsing high-dose oral glucocorticoids (40–60 mg/day prednisone-equivalent) as initial therapy for GCA, with tocilizumab as steroid-sparing add-on.
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi.org/10.1182/bloodadvances.2019000966 ASH guideline on initial corticosteroid therapy for adult immune thrombocytopenia, including dexamethasone pulse and prednisone 1 mg/kg/day options.
- Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi.org/10.1016/j.kint.2021.05.021 KDIGO guideline supporting prednisone-based regimens for childhood and adult nephrotic syndrome (e.g., 60 mg/m²/day initial pediatric dose).
- Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–2231. doi.org/10.1001/jama.2013.5023 REDUCE trial establishing non-inferiority of a 5-day vs 14-day prednisone 40 mg/day course in acute COPD exacerbations; basis of the GOLD recommendation.
- RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi.org/10.1056/NEJMoa2021436 RECOVERY trial demonstrating mortality benefit of dexamethasone 6 mg/day in oxygen-requiring or ventilated COVID-19; prednisone 40 mg/day is the accepted equivalent regimen.
- Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–293. doi.org/10.1136/ard.2005.038638 Systematic review demonstrating that adverse effects of low-dose glucocorticoid therapy in RA are modest and frequently not statistically different from placebo when assessed in randomized trials.
- Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–1838. doi.org/10.1136/ard.2008.100008 Meta-analysis quantifying adverse-event rates with low-to-medium-dose glucocorticoid therapy in inflammatory disease; primary source for the descriptive frequency tiers used in this monograph.
- Sullivan PJ, Sullivan PB. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi.org/10.1016/j.jaci.2020.10.003 NHLBI/NAEPP 2020 asthma guideline update; supports systemic glucocorticoid bursts (1–2 mg/kg/day in pediatrics, 40–60 mg/day in adults) for asthma exacerbations.
- Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy. Neurology. 2012;79(22):2209–2213. doi.org/10.1212/WNL.0b013e318275978c AAN guideline supporting oral corticosteroids (prednisone 60 mg/day for 5 days then taper) initiated within 72 hours of Bell’s palsy onset.